Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production
                    Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of
                    the Posterior Pituitary Gland

Lennart M. Reinke; Anna Katharina Seoudy; Friedericke Gärtner; Nathalie Rohmann; Dominik M. Schulte; Stefan Schreiber; Olav Jansen; Matthias Laudes

doi:10.1055/a-2093-1002

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes 2023; 131(09): 472-475
DOI: 10.1055/a-2093-1002

Letter to the Editor

Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of the Posterior Pituitary Gland

Lennart M. Reinke

¹Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

,

Anna Katharina Seoudy

¹Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

²Institute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

,

Friedericke Gärtner

³Institute of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

,

Nathalie Rohmann

²Institute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

,

Dominik M. Schulte

¹Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

²Institute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

,

Stefan Schreiber

¹Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

,

Olav Jansen

³Institute of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

,

Matthias Laudes

¹Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

²Institute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

› Author Affiliations

Abstract

Summary

The syndrome of inappropriate ADH-secretion (SIADH) is a common cause of low sodium levels with diverse aetiology. Here, we report a case of a 41 years old male patient diagnosed with SIADH and a good response to Tolvaptan therapy. Of interest, as a potential unique cause, magnetic resonance imaging revealed a micronodular structure in the posterior pituitary, while no other common cause of SIADH could be identified. Hence, to the best of our knowledge, this is the first case of a Tolvaptan-responsive SIADH associated with a pituitary micronodular structure.

Full Text

References

References
1 Ellison DH, Berl T. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356: 2064-2072
2 Mentrasti G, Scortichini L, Torniai M. et al. Syndrome of inappropriate antidiuretic hormone secretion (SIADH): Optimal management. Ther Clin Risk Manag 2020; 16: 663-672
3 Castellanos LE, Gutierrez C, Smith T. et al. Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification. Pituitary 2022; 25: 201-209
4 Sata A, Hizuka N, Kawamata T. et al. Hyponatremia after transsphenoidal surgery for hypothalamo-pituitary tumors. Neuroendocrinology 2006; 83: 117-122
5 Kanda M, Omori Y, Shinoda S. et al. SIADH closely associated with non-functioning pituitary adenoma. Endocr J 2004; 51: 435-438
6 Smedegaard SB, Jørgensen JO, Rittig N. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and subsequent central diabetes insipidus: A rare presentation of pituitary apoplexy. Case Rep Endocrinol 2019; 2019: 7592648
7 Gasparini S, Stein LM, Loewen SP. et al. Novel regulator of vasopressin secretion: Phoenixin. Am J Physiol Regul Integr Comp Physiol 2018; 314: R623-R628
8 Iovino M, Guastamacchia E, Giagulli VA. et al. Vasopressin secretion control: Central neural pathways, neurotransmitters and effects of drugs. Curr Pharm Des 2012; 18: 4714-4724
9 Refardt J, Winzeler B, Christ-Crain M. Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis. Clin Endocrinol 2019; 91: 22-32
10 Christ-Crain M. Vasopressin and copeptin in health and disease. Rev Endocr Metab Disord 2019; 20: 283-294
11 Săcărescu A, Turliuc M-D, Brănișteanu DD. Role of copeptin in the diagnosis of traumatic neuroendocrine dysfunction. Neuropeptides 2021; 89: 102167
12 Palmer BF, Clegg DJ. Electrolyte disturbances in patients with chronic alcohol-use disorder. N Engl J Med 2017; 377: 1368-1377
13 Shibamoto A, Namisaki T, Suzuki J. et al. Clinical significance of gamma-glutamyltranspeptidase combined with carbohydrate-deficient transferrin for the assessment of excessive alcohol consumption in patients with alcoholic cirrhosis. Medicines (Basel) 2021; 8: 39
14 Andresen-Streichert H, Müller A, Glahn A. et al. Alcohol biomarkers in clinical and forensic contexts. Dtsch Arztebl Int 2018; 115: 309-315
15 Jastrzębska I, Zwolak A, Szczyrek M. et al. Biomarkers of alcohol misuse: Recent advances and future prospects. Prz Gastroenterol 2016; 11: 78-89